Does ERG Expression Predict Docetaxel Benefit in Prostate Cancer?
Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy, according to analyses of two phase III clinical trials.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Prostate Cancer News Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Conferences | Docetaxel | Prostate Cancer | Taxotere